OZANIMOD (Zeposia®)

Clinical Indication

Adults with active disease as part of relapsing-remitting Multiple Sclerosis.


Not yet reviewed

Date of classification

December 2020

Review date

December 2020


Drugs not recommended for use in the Leicestershire Health Community because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.

All new drugs will be black until they have been through the appropriate approval process - then they will appear as a specific entry.